Revolution Medicines, Inc. (RVMD)Healthcare | Biotechnology | Redwood City, United States | NasdaqGS
183.95 USD
-2.93
(-1.568%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 181.75 -2.20 (-2.200%) ⇩ (July 13, 2026, 6:21 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:30 a.m. EDT
Revolution Medicines is currently riding a powerful wave of momentum driven by clinical milestones and regulatory fast-tracking for its pancreatic cancer drug. The stock has rallied sharply over the last two weeks, trading near its 52-week high, which validates the aggressive analyst consensus and the strong cash position relative to debt. While the company remains in a cash-burn phase with no earnings yet, the fortress-like balance sheet provides ample runway to navigate the binary risks inherent in biotechnology development. The options market is betting on a breakout above the 200 level, though protective puts suggest volatility is expected. For investors, this is a high-conviction growth play where the catalysts outweigh the lack of profitability, but the binary nature of the industry means the upside is capped by the risk of trial failure. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.070699 |
| AutoARIMA | 0.080500 |
| AutoETS | 0.080504 |
| MSTL_97 | 0.082202 |
| MSTL | 0.087864 |
| MSTL_74_97 | 0.104379 |
| MSTL_74 | 0.120771 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 13.09 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.021 |
| Excess Kurtosis | -0.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 29.153 |
| Market Cap | 39,107,117,056 |
| Forward P/E | -31.69 |
| Beta | 1.38 |
| Website | https://www.revmed.com |
As of July 11, 2026, 5:30 a.m. EDT: Speculators are positioning for upside with significant call open interest concentrated at the 200 and 210 strikes, creating a resistance wall near the current price. While put volume is substantial at lower strikes (115 to 130), indicating downside hedging or fear of a correction, the call positioning at higher levels suggests a bullish bias for the near-to-intermediate term. Implied volatility remains elevated on deep out-of-the-money puts, reflecting anxiety about a potential drop, but the call volume outweighs the put volume in the immediate expiration windows.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.870472 |
| Address1 | 700 Saginaw Drive |
| All Time High | 193.825 |
| All Time Low | 14.08 |
| Ask | 195.83 |
| Ask Size | 2 |
| Audit Risk | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 3,336,780 |
| Average Daily Volume3 Month | 3,367,129 |
| Average Volume | 3,367,129 |
| Average Volume10Days | 3,336,780 |
| Beta | 1.376 |
| Bid | 168.52 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 7.493 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 183.95 |
| Current Ratio | 6.795 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 185.998 |
| Day Low | 180.1 |
| Debt To Equity | 29.153 |
| Display Name | Revolution Medicines |
| Earnings Call Timestamp End | 1,778,099,400 |
| Earnings Call Timestamp Start | 1,778,099,400 |
| Earnings Timestamp | 1,778,097,600 |
| Earnings Timestamp End | 1,785,960,000 |
| Earnings Timestamp Start | 1,785,960,000 |
| Ebitda | -1,378,393,984 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -27.304 |
| Enterprise Value | 37,636,308,992 |
| Eps Current Year | -8.04433 |
| Eps Forward | -5.80498 |
| Eps Trailing Twelve Months | -7.1 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 159.7146 |
| Fifty Day Average Change | 24.235397 |
| Fifty Day Average Change Percent | 0.1517419 |
| Fifty Two Week Change Percent | 387.04718 |
| Fifty Two Week High | 193.825 |
| Fifty Two Week High Change | -9.875 |
| Fifty Two Week High Change Percent | -0.05094802 |
| Fifty Two Week Low | 34.0 |
| Fifty Two Week Low Change | 149.95 |
| Fifty Two Week Low Change Percent | 4.410294 |
| Fifty Two Week Range | 34.0 - 193.825 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,581,604,200,000 |
| Float Shares | 194,111,200 |
| Forward Eps | -5.80498 |
| Forward P E | -31.688309 |
| Free Cashflow | -606,370,880 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 883 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -1,125,553,024 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01895 |
| Held Percent Institutions | 0.95924 |
| Implied Shares Outstanding | 212,596,462 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. |
| Long Name | Revolution Medicines, Inc. |
| Market | us_market |
| Market Cap | 39,107,117,056 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_283775412 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -1,371,700,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 39,732,152,783 |
| Number Of Analyst Opinions | 22 |
| Open | 182.79 |
| Operating Cashflow | -1,057,470,976 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 650 481 6801 |
| Post Market Change | -2.199997 |
| Post Market Change Percent | -1.1959755 |
| Post Market Price | 181.75 |
| Post Market Time | 1,783,981,284 |
| Previous Close | 186.88 |
| Price Eps Current Year | -22.867039 |
| Price Hint | 2 |
| Price To Book | 24.54958 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.589 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.26087 |
| Region | US |
| Regular Market Change | -2.93001 |
| Regular Market Change Percent | -1.56786 |
| Regular Market Day High | 185.998 |
| Regular Market Day Low | 180.1 |
| Regular Market Day Range | 180.1 - 185.998 |
| Regular Market Open | 182.79 |
| Regular Market Previous Close | 186.88 |
| Regular Market Price | 183.95 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,705,462 |
| Return On Assets | -0.3753 |
| Return On Equity | -0.76672995 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 212,596,462 |
| Shares Percent Shares Out | 0.060599998 |
| Shares Short | 12,882,513 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 11,588,154 |
| Short Name | Revolution Medicines, Inc. |
| Short Percent Of Float | 0.064 |
| Short Ratio | 3.58 |
| Source Interval | 15 |
| State | CA |
| Symbol | RVMD |
| Target High Price | 263.0 |
| Target Low Price | 151.0 |
| Target Mean Price | 200.27045 |
| Target Median Price | 201.975 |
| Total Cash | 1,908,083,968 |
| Total Cash Per Share | 8.975 |
| Total Debt | 437,272,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -7.1 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 105.0209 |
| Two Hundred Day Average Change | 78.9291 |
| Two Hundred Day Average Change Percent | 0.75155616 |
| Type Disp | Equity |
| Volume | 1,705,462 |
| Website | https://www.revmed.com |
| Zip | 94,063 |